Showing results (201-210 of 3,351) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|September 18, 2018
Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trialRichard A Anderson, Rachel Remedios, Amy A Kirkwood, et al.
The Lancet. Oncology|October 1, 2018
National cancer control plans: a global analysisYannick Romero, Dario Trapani, Sonali Johnson, et al.
The Lancet. Oncology|September 8, 2018
The effect of natural disasters on cancer care: a systematic reviewRalph Xiu-Gee Man, David A Lack, Charlotte E Wyatt, et al.
The Lancet. Oncology|October 11, 2018
Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging GroupFrédéric E Lecouvet, Daniela E Oprea-Lager, Yan Liu, et al.
The Lancet. Oncology|October 13, 2018
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trialJudith Trotman, Sally F Barrington, David Belada, et al.
The Lancet. Oncology|March 7, 2022
Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysisDarren Jun Hao Tan, Cheng Han Ng, Snow Yunni Lin, et al.
The Lancet. Oncology|September 10, 2018
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trialViviana Galimberti, Bernard F Cole, Giuseppe Viale, et al.
The Lancet. Oncology|May 5, 2018
Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation OncologyRobert G Bristow, Brian Alexander, Michael Baumann, et al.
The Lancet. Oncology|May 5, 2018
Incorporating the patient experience into regulatory decision making in the USA, Europe, and CanadaPaul G Kluetz, Daniel J O'Connor, Katherine Soltys
The Lancet. Oncology|April 22, 2011
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority studyPhilippe Moreau, Halyna Pylypenko, Sebastian Grosicki, et al.
Pageof 336